17,734 Shares in TransMedics Group, Inc. $TMDX Purchased by Annex Advisory Services LLC

Key Points

• Annex Advisory Services purchased 17,734 TransMedics shares valued at approximately $1.48 million, while institutional investors collectively own 99.67% of the company.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but EPS of $0.44 fell short of the $0.50 consensus.
• TMDX shares opened at $70.78, well below their 12-month high of $156.00. Analysts maintain a consensus “Hold” rating with an average price target of $115.60.

Annex Advisory Services LLC acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 17,734 shares of the company's stock, valued at approximately $1,480,000. Annex Advisory Services LLC owned 0.05% of TransMedics Group as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TMDX. Braidwell LP increased its stake in TransMedics Group by 85.1% in the second quarter. Braidwell LP now owns 609,715 shares of the company's stock worth $40,497,000 after purchasing an additional 280,324 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of TransMedics Group by 5.5% during the first quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company's stock worth $51,355,000 after purchasing an additional 26,969 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of TransMedics Group by 6.1% during the second quarter. Wellington Management Group LLP now owns 515,973 shares of the company's stock valued at $34,271,000 after purchasing an additional 29,500 shares during the period. Wasatch Advisors LP boosted its stake in shares of TransMedics Group by 4.3% during the first quarter. Wasatch Advisors LP now owns 346,144 shares of the company's stock valued at $34,410,000 after purchasing an additional 14,296 shares during the period. Finally, Congress Asset Management Co. boosted its stake in shares of TransMedics Group by 11.0% during the third quarter. Congress Asset Management Co. now owns 252,952 shares of the company's stock valued at $21,109,000 after purchasing an additional 25,118 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Price Performance

Shares of TMDX stock opened at $70.78 on Friday. TransMedics Group, Inc. has a twelve month low of $60.10 and a twelve month high of $156.00. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of 18.20, a P/E/G ratio of 0.97 and a beta of 1.94. The stock has a fifty day simple moving average of $85.55 and a two-hundred day simple moving average of $82.90. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). The firm had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. TransMedics Group's quarterly revenue was up 20.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.92 EPS. On average, analysts predict that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on TMDX. Canaccord Genuity Group cut their price target on shares of TransMedics Group from $95.00 to $94.00 and set a "buy" rating on the stock in a report on Tuesday, October 13th. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, August 31st. UBS Group lowered their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating for the company in a research report on Wednesday, August 5th. Needham & Company LLC reissued a "buy" rating on shares of TransMedics Group in a research report on Friday, September 11th. Finally, Piper Sandler restated an "overweight" rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $115.60.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill bought 1,336 shares of the company's stock in a transaction on Friday, September 11th. The shares were bought at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the acquisition, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.